FIELD: medicine, immunology, microbiology.
SUBSTANCE: during 5 d running it is necessary to introduce lidocaine. Moreover, additionally, one should intramuscularly inject polyoxidonium at the dosage of 0.1 mg for 5 d running once daily. The innovation enables to match preparations that provide specific immunocorrection in case of this pathology, that is, it enables to increase natural body resistance and enables to provide stabilization of cellular membranes.
EFFECT: higher efficiency of correction.
2 dwg, 1 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATING PREVENTION OF HOSPITAL STRAIN FORMATION | 2010 |
|
RU2458138C2 |
| METHOD OF TREATING POSTTRAUMATIC INTRAOCULAR INFECTION | 1996 |
|
RU2126236C1 |
| METHOD OF SUPERFICIAL BURN TREATMENT APPLIED TO CHILDREN | 2008 |
|
RU2369415C1 |
| WAY OF PREVENTION OF SECONDARY IMMUNODEFICIENCY AT YOUNG STOCK OF CATTLE | 2008 |
|
RU2363483C1 |
| METHOD OF OPERATIVE TREATMENT OF BURN WOUNDS | 2018 |
|
RU2673806C1 |
| METHOD OF SELECTING THERAPY OF CHRONIC INFLAMMATORY DISEASES OF EYE SURFACE BASED ON CONTROLLED POTENTIATION OF EXUDATIVE REACTION BY MEANS OF MECHANICAL OR IMMUNE IMPACT | 2009 |
|
RU2421193C2 |
| FEED ADDITIVE FOR POULTRY | 2022 |
|
RU2788604C1 |
| METHOD FOR PREVENTION OF YOUNG CATTLE LEUKAEMIA | 2015 |
|
RU2586281C1 |
| METHOD OF EVALUATING STATE OF HUMAN HEALTH IN PREDICTION OF CLINICAL COURSE OF INFECTIOUS DISEASE | 2014 |
|
RU2595863C2 |
| TOPICAL AND EXTERNAL TILORONE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PURULENT-DESTRUCTIVE MUCOSAL AND SKIN DISEASES, SYSTEMIC DISEASES IN IMMUNODEFICIENCY STATES | 2008 |
|
RU2401104C2 |
